Does the media prefer ACAD or GMAB?

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 8 mentions for Genmab A/S. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Genmab A/S's score of -0.04 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACAD or ASND?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 14 mentions for Ascendis Pharma A/S. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Ascendis Pharma A/S's score of 0.73 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or BBIO?

In the previous week, ACADIA Pharmaceuticals had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 13 mentions for BridgeBio Pharma. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat BridgeBio Pharma's score of 0.26 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ACAD or RDY?

ACADIA Pharmaceuticals presently has a consensus price target of $32.59, indicating a potential upside of 28.81%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe ACADIA Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.65 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer ACAD or RDY?

In the previous week, ACADIA Pharmaceuticals had 15 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 2 mentions for Dr. Reddy's Laboratories. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Dr. Reddy's Laboratories' score of -0.23 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ACAD or AXSM?

In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Axsome Therapeutics. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 5 mentions for Axsome Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.50 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

ACADIA Pharmaceuticals (ACAD) Competitors

$25.30 +0.10 (+0.40%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$25.30 +0.00 (+0.02%)

As of 06/30/2026 07:28 PM Eastern

Compare

ACAD vs. GMAB, ASND, BBIO, RDY, and AXSM

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? MarketBeat compares ACADIA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ACADIA Pharmaceuticals include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Dr. Reddy's Laboratories (RDY), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does ACADIA Pharmaceuticals compare to Genmab A/S?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 8 mentions for Genmab A/S. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Genmab A/S's score of -0.04 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals presently has a consensus price target of $32.59, suggesting a potential upside of 28.81%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 38.07%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Genmab A/S's net margin of 21.05%. Genmab A/S's return on equity of 15.34% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Genmab A/S	21.05%	15.34%	8.94%

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.04	$391M	$2.20	11.50
Genmab A/S	$3.72B	4.60	$963M	$1.32	20.81

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 14 mentions for Ascendis Pharma A/S. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Ascendis Pharma A/S's score of 0.73 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to ACADIA Pharmaceuticals' net margin of 34.30%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

ACADIA Pharmaceuticals currently has a consensus target price of $32.59, suggesting a potential upside of 28.81%. Ascendis Pharma A/S has a consensus target price of $295.39, suggesting a potential upside of 10.75%. Given ACADIA Pharmaceuticals' higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

ACADIA Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.04	$391M	$2.20	11.50
Ascendis Pharma A/S	$814.57M	20.43	-$258M	$8.67	30.76

Summary

ACADIA Pharmaceuticals beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to BridgeBio Pharma's net margin of -124.42%. ACADIA Pharmaceuticals' return on equity of 9.61% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
BridgeBio Pharma	-124.42%	N/A	-65.81%

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ACADIA Pharmaceuticals presently has a consensus target price of $32.59, suggesting a potential upside of 28.81%. BridgeBio Pharma has a consensus target price of $92.90, suggesting a potential upside of 24.73%. Given ACADIA Pharmaceuticals' higher probable upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

ACADIA Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.04	$391M	$2.20	11.50
BridgeBio Pharma	$502.08M	29.05	-$724.93M	-$3.74	N/A

In the previous week, ACADIA Pharmaceuticals had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 13 mentions for BridgeBio Pharma. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat BridgeBio Pharma's score of 0.26 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ACADIA Pharmaceuticals beats BridgeBio Pharma on 11 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Dr. Reddy's Laboratories?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Dr. Reddy's Laboratories' net margin of 12.90%. Dr. Reddy's Laboratories' return on equity of 12.34% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

ACADIA Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.04	$391M	$2.20	11.50
Dr. Reddy's Laboratories	$3.58B	3.38	$456M	$0.58	25.01

ACADIA Pharmaceuticals presently has a consensus price target of $32.59, indicating a potential upside of 28.81%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe ACADIA Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, ACADIA Pharmaceuticals had 15 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 2 mentions for Dr. Reddy's Laboratories. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Dr. Reddy's Laboratories' score of -0.23 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ACADIA Pharmaceuticals beats Dr. Reddy's Laboratories on 11 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Axsome Therapeutics. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 5 mentions for Axsome Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.50 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals currently has a consensus target price of $32.59, indicating a potential upside of 28.81%. Axsome Therapeutics has a consensus target price of $258.95, indicating a potential upside of 5.79%. Given ACADIA Pharmaceuticals' higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

ACADIA Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.04	$391M	$2.20	11.50
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Axsome Therapeutics' net margin of -26.59%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

ACADIA Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Axsome Therapeutics on 13 of the 17 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.32B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	11.50	20.90	27.25	24.87
Price / Sales	4.04	341.80	540.68	102.84
Price / Cash	28.41	143.77	48.53	58.59
Price / Book	3.49	8.75	11.01	6.54
Net Income	$391M	$23.81M	$3.57B	$336.70M
7 Day Performance	8.30%	3.60%	2.31%	2.88%
1 Month Performance	17.57%	3.72%	1.39%	0.64%
1 Year Performance	18.45%	68.80%	36.71%	31.34%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.6362 of 5 stars	$25.30 +0.4%	$32.59 +28.8%	+17.3%	$4.32B	$1.07B	11.50	510	Trending News Analyst Forecast
GMAB Genmab A/S	4.6759 of 5 stars	$26.02 -0.4%	$37.93 +45.8%	+33.0%	$16.29B	$3.90B	19.71	3,029	News Coverage
ASND Ascendis Pharma A/S	4.2592 of 5 stars	$263.70 +1.1%	$295.39 +12.0%	+54.5%	$16.26B	$814.57M	30.42	1,189	Positive News Gap Up
BBIO BridgeBio Pharma	3.1665 of 5 stars	$72.01 +2.5%	$92.90 +29.0%	+72.5%	$13.76B	$502.08M	N/A	400	Positive News Gap Up
RDY Dr. Reddy's Laboratories	1.7067 of 5 stars	$14.88 -3.3%	N/A	-3.5%	$12.84B	$3.58B	25.65	27,527	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. GMAB, ASND, BBIO, RDY, and AXSM

How does ACADIA Pharmaceuticals compare to Genmab A/S?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. GMAB, ASND, BBIO, RDY, and AXSM

How does ACADIA Pharmaceuticals compare to Genmab A/S?

Does the media prefer ACAD or GMAB?

Do analysts prefer ACAD or GMAB?

Is ACAD or GMAB more profitable?

Which has better valuation and earnings, ACAD or GMAB?

Do institutionals and insiders hold more shares of ACAD or GMAB?

Which has more risk and volatility, ACAD or GMAB?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Does the media favor ACAD or ASND?

Is ACAD or ASND more profitable?

Do analysts rate ACAD or ASND?

Which has more volatility and risk, ACAD or ASND?

Do insiders and institutionals hold more shares of ACAD or ASND?

Which has stronger earnings and valuation, ACAD or ASND?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Is ACAD or BBIO more profitable?

Do institutionals & insiders hold more shares of ACAD or BBIO?

Do analysts rate ACAD or BBIO?

Which has more volatility and risk, ACAD or BBIO?

Which has higher valuation & earnings, ACAD or BBIO?

Does the media prefer ACAD or BBIO?

Summary

How does ACADIA Pharmaceuticals compare to Dr. Reddy's Laboratories?

Is ACAD or RDY more profitable?

Which has more volatility & risk, ACAD or RDY?

Do institutionals and insiders believe in ACAD or RDY?

Which has preferable valuation & earnings, ACAD or RDY?

Do analysts recommend ACAD or RDY?

Does the media prefer ACAD or RDY?

Summary

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Does the media refer more to ACAD or AXSM?

Do analysts recommend ACAD or AXSM?

Which has stronger earnings and valuation, ACAD or AXSM?

Is ACAD or AXSM more profitable?

Which has more risk & volatility, ACAD or AXSM?

Do institutionals and insiders believe in ACAD or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools